Back to News
Market Impact: 0.35
Nuvectis' NXP200 Shows Complete Responses In BRAF-Mutated Recurrent Gliomas
Source: Nasdaq
Healthcare & Biotech
Nuvectis Pharma reported positive expanded Phase 1b data for investigational second-generation BRAF inhibitor NXP200 in patients with recurrent or progressive BRAF V600-mutated gliomas. The report provided no numerical efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
NVCT0.55
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers
- Genmab shares jump 13% on colorectal cancer drug trial results